(IN BRIEF) Merck, a leading science and technology company, has announced its expectation to return to organic sales growth in fiscal 2024. This was revealed during the company’s Capital Markets Day. Despite challenging market conditions in its Life Science and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Electronics & Machinery, Financial, Germany, Healthcare, Management, Pharma & Biotech, Technology
Tagged artificial-intelligence, BAVENCIO™, Belén Garijo, Capital Markets Day, electronics, evobrutini, Healthcare, Internet of Things, IoT, Life Science, MAVENCLAD, Merck, semiconductor materials, Xevinapant
(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. These abstracts will showcase the latest research on Merck’s oncology portfolio, addressing … Read the full press release
Posted in Business, Germany, Healthcare, Management, Media, News, Pharma & Biotech, Science, Spain, Technology
Tagged BAVENCIO™, bladder, cancer treatment, colorectal, ERBITUX, ESMO 2023, head and neck, lung, Madrid, Merck, oncology, TEPMETKO, Xevinapant
First Health Canada approved treatment for rare and aggressive type of skin cancer MISSISSAUGA, ON, 26-Feb-2018 — /EuropaWire/ — Merck, which operates as EMD Serono in the US and Canada, and Pfizer Canada Inc. announced that Health Canada has approved BAVENCIO™ … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged BAVENCIO™, cancer #skin cancer, Dr. John Walker, EMD Serono, health, Health Canada, Kathy Barnard, Merck, Merkelcell carcinoma, Pfizer Canada, skin, tumour
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
